Resistance to crizotinib has also been reported in patients with inflammatory myofibroblastic tumor who presented with the BARBP2-ALK translocation and developed the ALKF1174L activation mutation after treatment with crizotinib [44]. The gene discussed is ALK; the disease is inflammatory myofibroblastic tumor.